SCHEMBL3299288

SCHEMBL3299288

Cc1cc(Nc2ccnc(Nc3ccc(S(=O)(=O)N4CCCC(O)(CN5C[C@@H](C)O[C@@H](C)C5)C4)cc3)n2)ccc1F

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CCNE1 P24864 2/20 0.38
CDK2 P24941 2/20 0.38
CDK4 P11802 1/20 0.38
IKBKB O14920 3/20 0.38
CHUK O15111 2/20 0.38
THRB P10828 1/20 0.37
TP53 P04637 1/20 0.37
MAPT P10636 1/20 0.37
LRRK2 Q5S007 5/20 0.37
CYP19A1 P11511 1/20 0.36
JAK2 O60674 2/20 0.36
JAK3 P52333 2/20 0.36
CYP2C9 P11712 1/20 0.36
NAMPT P43490 1/20 0.36
NPSR1 Q6W5P4 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3300040 0.92 IKBKB (0.41) CCNE1CDK2CDK4IKBKBCHUK
SCHEMBL3299578 0.91 MAPT (0.42) CCNE1CDK2CDK4IKBKBCHUK
SCHEMBL3300227 0.90 CDK4 (0.41) CCNE1CDK2CDK4IKBKBCHUK
SCHEMBL3306623 0.90 JAK2 (0.42) CCNE1CDK2CDK4IKBKBCHUK
SCHEMBL3301913 0.88 JAK2 (0.40) CCNE1CDK2CDK4IKBKBCHUK
SCHEMBL3306899 0.87 CDK2 (0.39) CCNE1CDK2CDK4IKBKBCHUK
SCHEMBL3300385 0.85 KMT2A (0.41) CCNE1CDK2CDK4IKBKBCHUK
SCHEMBL3298059 0.85 CDK2 (0.44) CCNE1CDK2CDK4IKBKBCHUK
SCHEMBL3298024 0.83 IKBKB (0.44) CCNE1CDK2CDK4IKBKBCHUK
SCHEMBL3295573 0.83 IKBKB (0.44) CCNE1CDK2CDK4IKBKBCHUK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100093668-A1 N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS SANOFI-AVENTIS (FR) 2010-04-15 US disclosed
US-20100093668-A1 N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS SANOFI-AVENTIS (FR) 2010-04-15 US disclosed
US-20100093668-A1 N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS SANOFI-AVENTIS (FR) 2010-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093668-A1 N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS CHUK, IKBKB, IKBKE CCNE1 180/4885CDK2 8/4885CDK4 55/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.